D
Daniel J. Lenihan
Researcher at Vanderbilt University Medical Center
Publications - 166
Citations - 9052
Daniel J. Lenihan is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Heart failure & Cancer. The author has an hindex of 32, co-authored 140 publications receiving 6193 citations. Previous affiliations of Daniel J. Lenihan include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter +15 more
TL;DR: This document describes the development and use of angiotensin-converting enzyme, a non-volatile substance that acts as a “spatially aggregating substance” to reduce the chances of heart attack in women.
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter,Stephan Achenbach,Stefan Agewall,Lina Badimon,Gonzalo Barón-Esquivias,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Scipione Carerj,Veronica Dean,Çetin Erol,Donna Fitzsimons,Oliver Gaemperli,Paulus Kirchhof,Philippe Kolh,Petros Nihoyannopoulos,Piotr Ponikowski,Marco Roffi,Antonio Vaz Carneiro,Stephan Windecker +34 more
TL;DR: No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.
Journal ArticleDOI
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline
Saro H. Armenian,Saro H. Armenian,Christina Lacchetti,Ana Barac,Joseph R. Carver,Louis S. Constine,Neelima Denduluri,Susan Dent,Pamela S. Douglas,Jean-Bernard Durand,Michael S. Ewer,Carol J. Fabian,Melissa M. Hudson,Mariell Jessup,Lee W. Jones,Bonnie Ky,Erica L. Mayer,Javid Moslehi,Kevin C. Oeffinger,Katharine Ray,Kathryn J. Ruddy,Daniel J. Lenihan +21 more
TL;DR: Recommendations for prevention and monitoring of cardiac dysfunction in survivors of adult-onset cancers were developed by an expert panel with multidisciplinary representation using a systematic review of meta-analyses, randomized clinical trials, observational studies, and clinical experience.
Journal ArticleDOI
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.
Biykem Bozkurt,Monica Colvin,Jennifer L. Cook,Leslie T. Cooper,Anita Deswal,Gregg C. Fonarow,Gary S. Francis,Daniel J. Lenihan,Eldrin F. Lewis,Dennis M. McNamara,Elfriede Pahl,Ramachandran S. Vasan,Kumudha Ramasubbu,Kismet Rasmusson,Jeffrey A. Towbin,Clyde W. Yancy +15 more
TL;DR: The intent of this American Heart Association (AHA) scientific statement is to summarize the current understanding of dilated cardiomyopathies, with special emphasis on recent developments in diagnostic approaches and therapies for specific cardiologyopathies.
Journal ArticleDOI
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano,Daniela Cardinale,Susan Dent,Carmen Criscitiello,Olexiy Aseyev,Daniel J. Lenihan,Carlo M. Cipolla +6 more
TL;DR: In this paper, the authors focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies.